GENZYME TO COLLABORATE WITH ABLYNX ON MULTIPLE SCLEROSIS RESEARCH PROJECT
(Thomson Reuters ONE) -
GHENT, Belgium, 18 May 2015 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today
announced that it has entered into an exclusive research collaboration with
Genzyme, a Sanofi company, to investigate Nanobodies® against a target that
plays an important role in multiple sclerosis (MS) and specifically aligns with
Genzyme's early-stage MS research programs involving neuroprotection and CNS
repair.
The neurodegeneration observed in MS is not directly targeted by existing
treatments. Genzyme's research efforts aim to address this unmet need by
targeting the underlying causes of MS disease progression and by developing
treatments to protect neurons and promote repair of CNS damage.
Under the terms of the agreement, Genzyme will have the right to perform in
vitro and in vivo research with Ablynx's Nanobodies in MS-relevant models in
return for an exclusivity fee. Upon completion of these studies, Genzyme will
have the option to negotiate a license agreement. Ablynx has already generated
potent Nanobodies against the specific target of interest and confirmed their
activity in pre-clinical models.
Commenting on the announcement, Dr Edwin Moses, CEO of Ablynx, said:
"As a leading biotech company, Genzyme is an ideal partner to demonstrate the
potential value of Ablynx's versatile Nanobody technology platform in MS. The
formatting flexibility of Nanobodies makes them promising candidates for
combining antibody-like selectivity and multi-specificity in a single molecule.
We are looking forward to working for the first time with Genzyme."
Johanne Kaplan, VP, Neuroimmunology Research, Genzyme, said:
"We look forward to collaborating with Ablynx to evaluate the potential of
Nanobodies against this CNS target, as this project supports our research that
includes the exploration of novel therapeutic platforms to address unmet needs
in multiple sclerosis."
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new medicines
which will make a real difference to society. Today, the Company has more than
30 proprietary and partnered programmes in development in various therapeutic
areas including inflammation, haematology, oncology and respiratory disease. The
Company has collaborations with multiple pharmaceutical companies including
AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co, Inc., Merck
Serono and Novartis. The Company is headquartered in Ghent, Belgium. More
information can be found on www.ablynx.com.
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative therapies
for patients affected by rare and debilitating diseases for over 30 years. We
accomplish our goals through world-class research and with the compassion and
commitment of our employees. With a focus on rare diseases and multiple
sclerosis, we are dedicated to making a positive impact on the lives of the
patients and families we serve. That goal guides and inspires us every day.
Genzyme's portfolio of transformative therapies, which are marketed in countries
around the world, represents groundbreaking and life-saving advances in
medicine. As a Sanofi company, Genzyme benefits from the reach and resources of
one of the world's largest pharmaceutical companies, with a shared commitment to
improving the lives of patients. Learn more at www.genzyme.com.
Genzyme(®) is a registered trademark of Genzyme Corporation. All rights
reserved.
For more information, please contact Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch(at)ablynx.com
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Jonathan Birt, Chris Welsh, Lindsey Neville
t: +44 203 709 5700
e : ablynx(at)consilium-comms.com
Pdf version of the press release:
http://hugin.info/137912/R/1921809/688832.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via GlobeNewswire
[HUG#1921809]
Unternehmensinformation / Kurzprofil:
Datum: 18.05.2015 - 07:00 Uhr
Sprache: Deutsch
News-ID 393828
Anzahl Zeichen: 5429
contact information:
Town:
Ghent/Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 208 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"GENZYME TO COLLABORATE WITH ABLYNX ON MULTIPLE SCLEROSIS RESEARCH PROJECT"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
